The Oral NK1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

This publication has 34 references indexed in Scilit:

• The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
  Journal of Clinical Oncology, 2003
• Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
  European Journal Of Cancer, 2003
• Establishing the dose of the oral NK₁ antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting
  Cancer, 2003
• Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869
  Cancer, 2002
• Potential of Substance P Antagonists as Antiemetics
  Drugs, 2000
• The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
  Neuropharmacology, 2000
• Neuropharmacology of emesis and its relevance to anti-emetic therapy
  Supportive Care in Cancer, 1998
• Effect of postchemotherapy nausea and vomiting on health-related quality of life
  Supportive Care in Cancer, 1997
• Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets
  Neuropharmacology, 1996
• Participation of Serotonin on Early and Delayed Emesis Induced by Initial and Subsequent Cycles of Cisplatinum‐Based Chemotherapy: Effects of Antiemetics
  The Journal of Clinical Pharmacology, 1993